Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 296

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 296
---
 a separate business opportunity for CogniMIR.

By 2025, an estimated 7.2 million Americans will
develop Alzheimer’s dementia. This number is expected to reach 13.8 million by 2060. Data suggest that annually about 500,000 cases
are detected in the US. Based on the population statistics the number of new AD cases in Europe can be estimated at 830,000 per year and
in Japan at 216,000 cases per year.

The potential worldwide market for AD diagnostic
tests is driven not only by AD patients, but also by the millions of aging baby boomers (approaching age 65 as well as those in their
50s) considered as high risk for AD. The US population of 65+ year-olds is currently 58 million and is estimated to reach 88.5 million
by 2050.

Studies from Harvard and Tufts Medical Center establish a high level
of interest in early detection of AD and report that 66% – 70% of respondents would like to be screened for AD even if no treatment
is available [Harvard study: Alzheimer’s Research & Therapy2013, 5:43; telephone survey of 2,678 respondents
from the US, France, Germany, Poland, Spain; Tufts study: Health Econ2012, 21:238; internet survey of 1,463 US respondents].
The Special Report titled “American Perspectives on Early Detection of Alzheimer’s Disease in the Era of Treatment”
published by the Alzheimer’s Association in the first half of 2025 states: “Nearly 4 in 5 Americans surveyed would want to know if they had Alzheimer’s disease before having symptoms, or before those symptoms interfered with their activities” (https://www.alz.org/getmedia/3d226bf2-0690-48d0-98ac-d790384f4ec2/alzheimers-facts-and-figures-special-report.pdf).

<div align='center'>156</div>

The survey also highlighted reasons for seeking an early stage AD diagnosis:

Initial focus

Since DiamiR’s 24-microRNA panel for risk
assessment of Alzheimer’s disease, CogniMIR is now analytically validated, DiamiR’s miRNA panel can be used
to screen patients for MCI and AD clinical trials. In order to satisfy CLIA requirements, for analytical validation, DiamiR performed
studies to demonstrate the assay’s performance characteristics, including:

|